I
n any injury, defense and protection mechanisms are initiated that aim to prevent further tissue damage and to restore organ integrity. For instance, central systems of our body such as the complement cascade and platelet thrombus formation are initiated in close spatiotemporal and functional proximity. 1 The complement system is an important part of innate immunity and consists of various tightly regulated soluble factors. It is activated by 3 distinct pathways converging in the formation of the C3 convertases C4bC2a and C3bBb, which mediate the cleavage of the central complement component C3 to C3b and C3a. 2 Whereas C3b further propagates the downstream complement cascade, the anaphylatoxin C3a formed in parallel constitutes a highly active protein contributing to tissue remodeling. 3, 4 Binding of C3a and its connate C5a fragment to their receptors C3aR or C5aR1 and C5aR2, respectively, on a variety of cell types mediates a broad range of effects during inflammation. [5] [6] [7] Besides its function in innate immunity, complement regulates a wide range of processes during tissue turnover, including angiogenesis, ischemia/reperfusion injury, sepsis, or organ healing. 3, 8, 9 Although knowledge about the cross-talk between complement and platelet activation is scarce, several reports about intersection points between complement activation and the soluble coagulation system exist. For instance, complement activation results in generation of thrombin, which in turn mediates platelet activation. 10 Very recently, it was shown that high concentrations of complement C3 are associated with an increased risk of venous thromboembolism 11 and that complement factors C3 and C5 contribute to platelet activation and fibrin deposition. 12 Furthermore, the human coagulation factor XIIa can activate the complement factor C1q and thereby initiate the classic pathway of complement activation. 13 On the other hand, C1 esterase inhibition can suppress all 3 complement pathways and the intrinsic coagulation cascade via kallikrein and factor XIIa. 13, 14 It is known that thrombin can generate C5a in the absence of C3. 15 Furthermore, C3aR-dependent formation of neutrophil extracellular traps (NETosis) on cellular and artificial surfaces triggers activation of the coagulation system, which links coagulation and complement activation to inflammation. 16 Similar to the complement activation process, platelet thrombus formation is a structured and coordinated process that involves adhesion to subendothelial matrix proteins, platelet spreading, and finally formation of fibrinogen bridges between platelets recruited from the bloodstream via activated glycoprotein (GP) IIb/IIIa (integrin αII b β 3 ) receptors, resulting in the development of a thrombotic clot. 17 It has been shown that complement activation and the formation of C3b can occur on the platelet surface and that C3b can bind to the platelet receptor P-selectin, [18] [19] [20] which is expressed on platelet activation. However, a role of C3a for platelet-complement cross-talk has not been addressed so far in vivo. A potential importance of this finding has been highlighted recently; a whole-exome sequencing approach of a patient with severe and complex hemostatic abnormalities revealed a possible contributing frameshift mutation in C3aR1. 21 A role of complement deposition on platelets has been suggested, 20 although the exact mechanisms detailing how complement components bind to platelets and the relevance of this binding for platelet functions remain elusive. Because complement deposition on the platelet surface is of pathophysiological relevance in several immune-mediated diseases with a prothrombotic state, including paroxysmal nocturnal hemoglobinuria, atypical hemolytic-uremic syndrome, or atherosclerosis, 22 it is important to characterize the underlying mechanisms connecting complement activation to thrombus formation. This is of particular importance in diseases featuring thromboinflammation such as stroke or myocardial infarction. 22, 23 Already in the early phase of myocardial infarction, accumulation of the terminal complement complex was detected after reperfusion, and inhibition of the complement cascade was demonstrated to re-
Clinical Perspective
What Is New?
• Murine and human platelets express the anaphylatoxin receptor C3aR. It can be detected in aspirates of patients with myocardial infarction, and its expression in patients with coronary artery disease correlates with the activated platelet fibrinogen receptor glycoprotein IIb/IIIa. • Using several in vitro, ex vivo, and in vivo approaches and different genetic mouse models, we identified the anaphylatoxin receptor C3aR and its corresponding ligand C3a as platelet activators via intraplatelet signaling resulting in activated glycoprotein IIb/IIIa, which mediates intravascular thrombosis, stroke, and myocardial infarction.
• We have identified a novel point of intersection between innate immunity and thrombosis with relevance for the thrombotic diseases stroke and myocardial infarction.
What Are the Clinical Implications?
• Complement components involved in the development of atherothrombosis need to be further studied in translational and clinical settings of stroke and coronary heart disease.
• The identified C3a-C3aR axis on platelets may be a promising diagnostic and therapeutic target to approach underlying thromboinflammatory mechanisms of stroke and myocardial infarction.
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duce myocardial damage after myocardial infarction. 24, 25 In stroke, components of the complement system have been shown previously to be involved in tissue remodeling processes such as neural plasticity, and inhibition of complement components was proposed as a therapeutic approach after neural ischemia. 26, 27 Mice deficient for the central complement component C3 or mice treated with a C3aR antagonist are protected from transient focal cerebral ischemia, 28 although the role of platelet-derived anaphylatoxin receptors has not been addressed so far.
Here, we sought to investigate whether expression of complement C3aR holds a pathophysiological relevance for platelet function, hemostasis, and thrombosis in pathologies such as stroke or myocardial infarction.
METHODS
Please see the online-only Data Supplement for expanded methods. Requests by researchers to access the data, analytical methods, and study materials for the purposes of reproducing the results or replicating procedures can be made to the corresponding author, who manages the information.
Study Approval
For experiments with human material, written informed consent was received from participants before inclusion in the study (approval 270/2011B01).
All animal experiments were approved by governmental authorities and performed in accordance with the German law guidelines of animal care (approval M10/12).
Immunofluorescence Staining
Human thrombi harvested from aspirates of the coronary arteries of patients with myocardial infarction undergoing percutaneous coronary intervention were analyzed by immunofluorescence microscopy. Samples were stained with primary antibodies: antihuman C3aR and antihuman or corresponding control immunoglobulin G followed by a secondary antibody conjugated with ALEXA fluorochromes.
Flow Cytometry Analysis
Human platelets in freshly collected blood were evaluated for the surface expression of C3aR and P-selectin (CD62P) after gating for the platelet-specific marker CD42b. Isolated murine platelets for flow cytometric analysis were stained with the anti-mouse antibodies fluorescein isothiocyanate (FITC)-anti-P-selectin, FITC-anti-GPVI, FITC-anti-GP Ibα, FITC-anti-integrin αIIbβIII, FITC-anti-integrin α5, and FITC-anti-integrin β3. Activated GPIIb/IIIa was detected with fibrinogen-Alexa 488 or PE-antiintegrin GPIIb/IIIa. Samples were analyzed with a FACSCalibur flow cytometer (Becton Dickinson, Heidelberg, Germany).
Mice

C57BL/6 mice and C3
−/− mice were obtained from The Jackson Laboratory. C3aR −/− mice were a kind gift from Dr Rick Wetsel (University of Houston, TX), and C5aR −/− mice were kindly provided by Dr Craig Gerard (Harvard Medical School, Boston, MA). Spa.1 −/− mice were provided by Dr Yasutoshi Agata (Kyoto University, Japan) and bred with the C3aR −/− mice to obtain a Spa.1
−/− double-knockout strain. GPIbα −/− mice were kindly provided by Dr Jerry Ware (University of Arkansas for Medical Sciences). All strains were on a C57BL/6 background, and genotypes were confirmed by polymerase chain reaction. Littermates were used in all experiments as control animals.
Isolation of Human and Murine Platelets
Human platelets were isolated according to standard protocols. Murine platelet preparations were obtained with a modified protocol. For activation, isolated platelets were stimulated with 20 µmol/L ADP or 0.01 U/mL thrombin and/or C3a (as indicated in figure legends) at room temperature.
Western Blotting
Whole-cell lysates were separated by SDS-PAGE and subjected to Western blot. Membranes were incubated with primary antibodies (anti-mouse C3aR, anti-human C3aR, anti-Spa-1, clone M-300, anti-RAP1, anti-GAPDH, anti-mouse phosphophosphoinositide 3-kinase [PI3K], anti-mouse total PI3K, or antitubulin). Membranes were scanned with the Odyssey Infrared Imaging System (LI-COR, Bad Homburg, Germany) and analyzed. ) shear rates for 10 minutes. 29 Experiments were recorded with a video recorder linked to a microscope (optical objectives, ×20 and ×40; Carl Zeiss), and adherent platelets were quantified.
Flow Chamber Assay
Platelet Spreading
Isolated murine platelets were incubated on fibrinogencoated and BSA-blocked cover slides for 30 minutes at room temperature. Platelets were fixed and permeabilized with PHEM buffer (100 mM PIPES, 5,25 mM HEPES pH 7.0, 10 mM EGTA, 20 mM MgCl 2) containing paraformaldehyde and NP-40, stained with rhodamin-phalloidin, and analyzed with an Axio Observer Z.1 microscope (Zeiss).
Scanning Ion Conductance Microscopy
Isolated wild type (WT) and C3aR −/− platelets were stimulated with thrombin and allowed to adhere for 30 minutes to fibrinogen-coated culture plates. Platelets were then fixed with 4% paraformaldehyde and mounted into the scanning ion conductance microscopy setup. Platelet morphology was analyzed with custom-written software. Briefly, the cell contour was determined automatically with a height threshold of 50 nm and processed to calculate the morphology parameters (area A, height, and circularity C=4πA/P 2 with perimeter P).
Immunoprecipitation
Resting and stimulated platelets were lysed by adding an equal amount of lysis buffer. Samples were incubated with anti-C3aR antibody. Protein G-Sepharose was added, and samples were incubated overnight at 4°C with rotation.
Immunoblotting was performed as indicated.
SDS-PAGE and In-Gel Digestion
Complete protein eluates of the pull-down experiments were submitted to a short run (1 cm in length) on 1-dimensional SDS-PAGE. The proteins were visualized by staining, and the corresponding gel sectors were excised and subjected to tryptic in-gel digestion. The resulting peptide mixtures were desalted before liquid chromatography (LC)/mass spectrometry measurement.
Nanoscale LC Coupled to Tandem Mass Spectrometry Analysis
LC-mass spectrometry analysis was carried out on a nanoscale LC (Easy-nLC, Thermo Fisher Scientific, formerly Proxeon Biosystems) coupled to a LTQ-Orbitrap-XL (Thermo Fisher Scientific). Mass spectrometry data were processed with the MaxQuant software suite, peptide sequences were retrieved by use of the Andromeda search engine, and data were searched against the Uniprot mouse database.
Rap1 Activation and Pull-Down Assay
For detection and pull-down of activated Rap1 (GTP-Rap1), a commercially available kit (affinity precipitation assay, Merck Millipore) was used.
Measurement of Cytosolic Ca
2+
Concentration
Washed murine platelets were loaded with 5 μmol/L fura-2 acetoxymethylester in the presence of 0. ].
Platelet Aggregometry
Aggregation of human or murine platelets was estimated from light transmission determined with a luminoaggregometer (model 700, ChronoLog). Platelets were activated with 20 µmol/L ADP, C3a in different doses, or control protein (scrambled C3a) at the indicated concentrations. Analysis was performed with the Aggrolink8 software (ChronoLog).
Bleeding Time
Mice were anesthetized, and a 3-mm segment of the tail tip was removed with a scalpel. Tail bleeding was monitored by gentle absorption of the blood with filter paper at 20-second intervals without making contact with the wound site.
Intravital Microscopy
Intravital microscopy and induction of platelet thrombus formation in vivo were carried out as described before.
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Stroke Model
All stroke experiments were performed in accordance with the recently published Animal Research: Reporting of In Vivo Experiments guidelines (nc3rs) and performed as described before.
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Myocardial Infarction Model
All myocardial infarction experiments were performed as described before.
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Statistics
Data are provided as mean±SD; n represents the number of experiments. All data were tested for significance with the unpaired Student t test and 1-way or 2-way ANOVA with the Bonferroni post hoc test. Results with values of P<0.05 were considered statistically significant.
RESULTS
Various components of the complement cascade have previously been detected on platelets isolated from human subjects, particularly after platelet activation. 20 Strikingly, in our large collective of patients with coronary artery disease, expression of C3aR was strongly correlated with the expression of the activated fibrinogen receptor GPIIb/IIIa (with the use of an activationspecific antibody; r=0.59, P<0.001; Figure 1A and 1B). We furthermore observed a significant correlation in the subgroup of patients receiving no P2Y 12 inhibitor (Spearman rank coefficient r s =0.60, P<0.001; n=410 patients) and in the subgroup of patients receiving P2Y 12 inhibitors (r s =0.53, P<0.001; n=91 patients), as indicated in Figure I in the online-only Data Supplement. The distribution of different P2Y 12 inhibitors is depicted in Table  I in the online-only Data Supplement. In line with this finding, C3aR was detected in platelets isolated from both murine and human blood ( Figure 1C and 1E). Although a marginal expression of C3aR was observed on the surface of unstimulated platelets, ADP-induced platelet activation resulted in a significant increase in the expression levels of C3aR ( Figure 1F and 1G). Overall expression of C3aR in lysed platelets showed no significant differences among resting, ADP-, or C3a-stimulated platelets ( Figure II in the online-only Data Supplement).
In light of the significant expression of C3aR on activated platelets, we assessed whether C3aR-mediated signaling affects the function of platelets during bleeding. Initially, tail bleeding time was assessed in C3-deficient mice because C3 is the central complement component and key for the activation of all 3 complement pathways. Prolonged bleeding time (3 times longer compared with control mice) was observed in the absence of C3 (Figure 2A) , which is in line with previous reports. 32 Similar bleeding time was observed in GPIbα −/− mice, resembling the phenotype of the Bernard-Soulier syndrome in which increased bleeding time is seen as a result of thrombo- Coomassie Blue staining of the polyvinylidene fluoride membranes after blotting served as loading control. F, ADP-stimulated (20 µmol/L) human platelets in platelet-rich plasma were fixed with 1% paraformaldehyde and spun on poly-l-lysine coverslips. Permeabilized platelets were analyzed for expression of CD62-P (green) and C3aR (red) with a Zeiss LSM 800 microscope (×63 objective; area of interest cropped ×4.7). G, Human platelets were isolated, stimulated with ADP (20 µmol/L), and analyzed by flow cytometry for surface expression of C3aR. Figure 2A ). Given that C3 is activated on the surface of activated platelets with consequent generation of C3a 18 and the increased expression of C3aR ( Figure 1G ), we next analyzed bleeding time after tail injury in C3aR −/− mice. In line with the findings described above, mice deficient for C3aR showed a significantly prolonged time to bleeding arrest compared with wild-type C57BL/6 (WT) littermate controls ( Figure 2B ). This effect could not be attributed to altered platelet numbers in these mice because both WT and C3aR −/− mice showed comparable peripheral platelet counts ( Figure III in the online-only Data Supplement). In contrast to C3aR −/− animals, no significant increase in bleeding time was observed in mice deficient for C5aR ( Figure IV in the online-only Data Supplement), also a G protein-coupled receptor that binds the complement activation product C5a. 3 Supporting a role for C3aR in the control of bleeding, pharmacological inhibition of C3aR with a small-molecule antagonist (SB290157, 750 µg/mouse IP) resulted in prolonged bleeding time resembling the phenotype of C3 −/− and C3aR −/− mice (Figure 2C) . Prolonged tail bleeding time in C3 −/− mice was reversed on intravenous administration of C3a peptide (15 µg per mouse); a peptide with scrambled amino acid sequence was used as negative control ( Figure 2D ).
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Because platelets have to firmly adhere to the extracellular matrix and spread before additional platelets can be recruited to the evolving thrombus, 17 we tested whether C3aR-mediated signaling assists in the process of platelet adhesion. Although C3a alone was not sufficient to mediate platelet adhesion (data not shown), a significant increase in platelet adhesion to fibrinogencoated chambers under dynamic flow conditions was observed on C3a stimulation ( Figure 3A) . Furthermore, coimmobilization of C3a with fibrinogen increased platelet adhesion (Figure VA in the online-only Data Supplement), and adhesion of murine C3aR −/− platelets to fibrinogen was significantly reduced compared with WT platelets (Figure VB in the online-only Data Supplement). The difference was no longer present when C3a-des-arg 7 was used ( Figure VI in the onlineonly Data Supplement). Such differences in platelet adhesion were not a consequence of differential expression levels of adhesion molecules because platelets isolated from either WT or C3aR −/− mice showed similar expression of important platelet adhesion molecules ( Figure 3B ). In contrast, Ca 2+ influx in response to thrombin, a key event during platelet adhesion to extracellular matrix proteins, was significantly reduced in platelets from C3aR −/− compared with WT mice or in WT platelets treated with a C3aR inhibitor ( Figure 3C and 3D). Furthermore, the deficiency of C3aR resulted in decreased spreading capacity of thrombin-stimulated platelets ( Figure 3E ). A similar result was obtained with a C3aR inhibitor (Figure VII in the online-only Data Supplement). To investigate the influence of C3aR on platelet spreading on a single-cell level, WT and C3aR −/− platelets were analyzed with scanning ion conductance microscopy. Scanning ion conductance microscopy allows label-free, quantitative characterization of platelet 3-dimensional morphology with high resolution. After 30 minutes of adhesion on immobilized fibrinogen, thrombin-stimulated (0.01 U/mL) C3aR −/− platelets exhibited significantly reduced spreading area, increased height, and more irregular cell shape compared with WT platelets (Figure 3F ).
Given our findings that C3aR-mediated signaling appears to modulate platelet adhesion and spreading, consequently affecting thrombus formation, we next investigated the pathophysiological relevance of these observations using in vivo models of experimental myocardial infarction and stroke. 30, 31 Focal cerebral ischemia was induced in WT and C3aR −/− mice. Notably, C3aR −/− platelets were stimulated with 0.01 U/mL thrombin and allowed to adhere to immobilized fibrinogen before the spreading area of rhodamin-phalloidin-stained platelets was measured by microscopy. Data represent mean±SD. n=5. *P<0.05 for C3aR −/− platelets vs platelets isolated from WT mice. Scale bars: 10 µm. F, Isolated WT and C3aR −/− platelets were stimulated with 0.01 U/mL thrombin, and adhesion to immobilized fibrinogen was analyzed after 30 minutes. Area, height, and circularity of paraformaldehyde-fixed platelets were analyzed with scanning ion conductance microscopy (SICM). Data represent mean±SD. n=26 platelets from n=4 independent experiments each. *P<0.05. Bottom, Representative SICM topography images. The cell contour (red) was traced to quantify cell area, height, and circularity. 
C3aR
−/− mice compared with WT mice (Figure 4A-4C ). Addressing the role of C3aR in human heart disease, we could identify the presence of C3aR on platelets in thrombi aspirated from the coronary arteries of 5 patients with myocardial infarction during percutaneous coronary intervention ( Figure 5A ). Thus, we went on to study the role of the platelet C3aR in experimental myocardial infarction. Similar to the results in experimental stroke, induction of myocardial infarction with an ischemia/reperfusion model resulted in significantly reduced myocardial necrosis and better left ventricular function in the C3aR −/− compared with WT mice (Figure 5B-5E  and Tables II and III in the online-only Data Supplement). If platelets were depleted, this difference was no longer observed, highlighting the cell-specific functional role of this receptor on platelets ( Figure 5B and 5C ). The difference between WT and C3aR −/− mice persisted, however, after neutrophil depletion ( Figure 5C ). Reduced myocardial necrosis was associated with an increase in left ventricular function in C3aR −/− mice compared with WT mice, which was not observed in the absence of platelets ( Figure 5D and 5E), suggesting an important role of the platelet C3aR in this setting. We next investigated whether the reduced infarct volume observed in C3aR −/− mice was associated with the expression of C3aR specifically on platelets. For this purpose, C3aR −/− mice were reconstituted with either C3aR −/− or C3aR +/+ platelets (1×10 8 platelets per mouse) before tail bleeding time was analyzed as a measure of platelet thrombosis. The presence of the C3aR on platelets in C3aR −/− mice reconstituted with platelets from C3aR +/+ mice was verified by Western blot 24 hours after adoptive transfer (data not shown). The prolonged bleeding time observed in C3aR −/− mice was reversed in the presence of WT platelets ( Figure 6A ). Consistent with our hypothesis, flow cytometric analysis of platelets showed lower expression of the activated GPIIb/ IIIa fibrinogen receptor, critical for the triggering of the final events of platelet thrombus formation, in C3aR −/− platelets with conventional aggregometry. WT platelets prestimulated with 2 µmol/L ADP show increased aggregation after the addition of C3a (time lag, 5 seconds), which was dose-dependent. In C3aR −/− platelets, aggregation after stimulation with ADP and increasing doses of C3a was significantly reduced vs WT platelets. E and F, Mesenteric arterioles were injured by topical application of 20% FeCl 3 , and thrombus formation was monitored by intravital microscopy. In C3aR −/− mice, the time to vessel occlusion was significantly prolonged in comparison to WT mice. Data represent mean±SD, n=6 (WT), n=8 (C3aR Figure 6B and 6C). To determine whether C3aR-mediated surface expression of activated GPIIb/IIIa is the mechanism underlying differential platelet function in the absence of C3aR, ADP-activated (20 µmol/L) murine platelets of C3aR −/− and C3aR +/+ were stimulated with recombinant C3a. Stimulation of ADP-preactivated platelets with C3a resulted in increased platelet aggregation in a dose-dependent manner ( Figure 6D) . Similar results were obtained with human platelets (Figure X in the online-only Data Supplement). The difference was no longer present if C3a-des-arg 34 ( Figure IIA in the online-only Data Supplement) or other platelet agonists such as collagen and thrombin were used (Figure XIB and XIC in the online-only Data Supplement), suggesting the specificity of our findings. To directly assess thrombus formation in vivo, an established intravital microscopy model of FeCl 3 -induced thrombus formation of the mesenteric vasculature was used. 29 Supporting our previous findings, the time required to vessel occlusion was significantly prolonged in C3aR −/− compared with WT or C5aR −/− mice ( Figure 6E and 6F). Signaling via the GTPase Ras-related protein Rap1b (Rap1b) is critical for thrombus formation in mice. 35 Rap1 was detected after immunoprecipitation of platelet lysates with an anti-C3aR antibody ( Figure 7A ). Further proteins associated with C3aR are listed in Table  IV in Figure 7C ). To assess the influence of P2Y 12 inhibition on C3aR expression, we analyzed platelets treated with inhibitors of P2Y 1 and P2Y 12 in vitro by flow cytometry. We observed a significantly reduced C3aR expression in platelets treated with the P2Y 12 inhibitor, but not with the P2Y 1 inhibitor ( Figure  XIIA in the online-only Data Supplement). Because inhibition of P2Y 12 , but not P2Y 1 , significantly reduces Rap1 activity in stimulated murine platelets, P2Y 12 seems to be the relevant ADP receptor in this setting ( Figure XIIB in the online-only Data Supplement). C3a is a cleavage product of C3. 3 In the absence of C3 using platelets isolated from C3 −/− mice, the effect of Rap1b activation by C3a is still detectable ( Figure XIII in the online-only Data Supplement). To determine the role of C3aR for Rap1b signaling in platelets, Rap1b GTPase-activating protein Spa.1 knockout mice, which show constitutively active Rap1b, 36 were back-crossed with C3aR −/− mice (Figure 8A) . These C3aR −/− ×Spa.1 −/− double-knockout mice, which also have constitutively activated Rap1b (Figure 8B) , were tested in tail bleeding time experiments, in vitro adhesion, and aggregation. Expression of Spa.1 was confirmed in isolated activated platelets ( Figure Figure 8D ). From previous studies, it is known that platelet stimuli such as ADP result in phosphorylation of PI3K and increased Rap1 activity. 37 To further shed light on the signaling pathways involved in platelet C3aR signaling via Rap1b, we found that stimulation of platelets with C3a results in increased Rap1b activity on top of platelet stimulation by ADP. Accordingly, C3a and ADP-C3a costimulation resulted in increased phosphorylation of PI3K ( Figure XVII in the online-only Data Supplement).
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DISCUSSION
The complement cascade and platelet activation are important systems to preserve tissue integrity and organ function. Here, we show that the complement C3aR is expressed on mouse and human platelets and document a functional role of this receptor for platelet functions such as firm adhesion or platelet spreading, important for thrombus formation in vivo. Furthermore, we show that the C3a-C3aR axis activates the small GTPase Rap1b, promotes GPIIb/IIIa activation, and contributes to platelet aggregation and thrombus formation.
Early in vitro studies using guinea pig platelets suggested expression of the anaphylatoxin receptor C3aR on platelets. 38 Furthermore, the complement component C3 was found to be present in human plasma clots. 39 A role of the platelet C3aR was previously demonstrated in the context of the prostaglandin metabolic pathway. 40 Here, we demonstrate by Western blot and flow cytometry that C3aR is expressed and upregulated on platelets on activation.
Recently, it was observed that P2Y 12 inhibitors resulted in modification of G protein-coupled receptors/ GPIIb/IIIa. In the analysis of our patients, there was a significant correlation between C3aR expression and activated GPIIb/IIIa that was independent of the presence of a P2Y 12 inhibitor. At this point, however, we cannot entirely rule out an influence of P2Y 12 inhibition because of the small patient numbers, particularly in the group with no antiplatelet medication.
Expression of other platelet receptors relevant for platelet function was not different between WT and C3aR-deficient animals. In vitro, C3aR on platelets regu- A, Rap1 detection after immunoprecipitation of platelet lysates with an anti-C3aR antibody. Protein eluates of pull-down experiments using isolated murine platelets and an anti-C3aR antibody were subjected to nanoscale liquid chromatography tandem mass spectrometry (MS) analysis. Processing of the retrieved MS data with Max Quant/Andromeda software suite revealed Rap1 as a C3aR receptor interaction partner. Shown are representative mass spectra of the 3 peptides INVNEIFYDLVR, LVVLGSGGVGK, and YDPTIEDSYR identifying Rap1. The table shows the posterior error probability (PEP) of the 3 peptides identifying Rap1. A PEP <0.01 indicates that the peptide was identified with a probability of >99%. B, Rap1 pull-down assay for detection of activated Rap1 in murine platelet lysates of wild-type (WT) and C3aR −/− mice stimulated with C3a or control (Ctrl) peptide (200 nmol/L). Activated Rap1 in murine platelet lysates was isolated with glutathione S-transferase (GST)-tagged Sepharose, subjected to SDS-PAGE, blotted, and detected with an activationspecific Rap1 antibody. The amount of total Rap1 is equal in each sample. One representative blot of 3 experiments is depicted. The bar chart shows the densitometric analysis of Rap1-GTP expression. Data represent mean±SD. n=3. *P<0.01. Control was set as the 100% value. C, Rap1 pull-down assay for detection of activated Rap1 in murine platelet lysates of WT mice stimulated with ADP (20 µmol/L), or ADP and C3a (200 nmol/L), or ADP and C3a and the C3aR inhibitor (Inh.) SB290157 (10 µmol/L). Activated Rap1 in murine platelet lysates was isolated with GST-tagged Sepharose, subjected to SDS-PAGE, blotted, and detected with an activation-specific Rap1 antibody. The amount of total Rap1 is equal in each sample. One representative blot of 3 experiments is depicted. The bar chart shows the densitometric analysis of Rap1-GTP expression. Data represent mean±SD. n=3. ADP stimulated platelets were set as the 100% value. *P<0.01. a/z (amu) indicates atomic mass unit; and Plt, platelets.
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lates specific aspects of their function. For instance, we could measure a significant increase in platelet adhesion, spreading, and aggregation after stimulation of platelets with a C3a peptide. Similarly, it was observed before that aggregation of human platelets after stimulation with C3a was more pronounced. 41 One explanation is the reduced activation-dependent increase of the cytosolic Ca 2+ concentrations in C3aR −/− platelets, which reflects an important step in platelet thrombus formation on stimulation with different platelet agonists. 42 A previous study had observed cleavage of C3 into C3b on the platelet surface, 43 although the potential role of C3a or the C3aR for platelets was not addressed. Here, we demonstrated that C3aR-deficient platelets show reduced spreading on fibrinogen, which is one of the later events during platelet thrombus formation before fibrinogen bridges are built by activated GPIIb/IIIa on aggregating platelets. Thrombosis is a determining factor and often decisive event in various (patho-) physiological settings such as provisional closure of an endothelial wound or vessel occlusion in stroke and myocardial infarction. 44 Using aggregometry as the gold standard for analyzing ex vivo thrombus formation, we observed a dose-dependent effect of C3a on prestimulated platelets on aggregation in vitro. In turn, C3aR −/− mice, but not C5aR −/− mice, had a prolonged time to vessel occlusion after vascular injury. This was attributable to the presence of C3aR on platelets, as shown here by experi- 45 In terms of tail bleeding time, C3aR −/− mice had a prolonged bleeding time, which could be reproduced with a pharmacological approach by the injection of a C3aR antagonist peptide. To identify potential mechanisms mediating the observed effects of the C3aR on platelet function, we analyzed proteins associated with the C3aR on platelets. Recently, generation of Rap1b knockout mice revealed a severely prolonged bleeding time phenotype. 35 Rap proteins are small GTPases that belong to the Ras family, 46 with Rap1b being the most abundant Ras protein in platelets. 47 We observed that Rap1b was associated with the C3aR on platelets and that C3a treatment resulted in increased Rap1 activity in platelets. To follow up on these observations, we generated C3aR −/− ×Spa.1 −/− double-knockout mice to verify these observations in vivo. Activated Rap1b (Rap1b-GTP) is inactivated (Rap1b-GDP) by Spa.1, 48 and Spa.1 knockout mice have constitutively active Rap1. 36 In line with our previous findings, C3aR The relevance of platelets in diseases with a prothrombotic state involving complement activation has been known for a long time, although the direct connection between platelets and the complement system remains largely uncharacterized. 49 In experimental stroke, inhibition of complement activation and endothelial-platelet-leukocyte interactions with a sialyl Lewis×(sLe x ) -glycosylated complement inhibitory protein results in neuronal protection. 26 A potential role for C3aR in stroke has also been proposed before, although the role of C3aR in this disease has so far been attributed mainly to inflammation. 50 C3 −/− mice are protected from transient focal cerebral ischemia, 28 but the relevance of platelet-derived complement has not been addressed so far.
In cases in which clear complement targets can be identified (as in hereditary angioedema or nocturnal hemoglobinuria), complement therapeutics have already been successfully introduced into the clinic and are applied in patients. 51, 52 There are several human trials [53] [54] [55] [56] using complement inhibitors in patients undergoing coronary artery interventions. A benefit, however, could be shown only in specific patient settings. Because no drug targeting the C3a-C3aR axis has been applied in clinical studies with patients with atherothrombosis so far, the available studies do not necessarily contradict our data. Many of the compounds tested for trials in coronary artery disease that have been discontinued were designed to target underlying multifaceted and complex pathophysiologies such as vascular inflammation or ischemia/reperfusion injury. 51 In these disorders, many parallel mechanisms are involved, and the influence of complement is still a matter of in-depth investigation. Suddenly, the unsatisfactory results obtained for soluble complement receptor 1 (TP10) 57 and pexelizumab, 56 which targets C5 downstream of C3a analyzed in our project, have left a bitter taste and may have had a negative impact on the field. For such complex indications, the key to success may be to use complement drugs not as single therapies but (in consonance with their name) as complementary therapies. Clearly, more basic research and additional tests are required in this context. Here, we provide an additional piece of knowledge to the puzzle, which may help to approach (specific) complement therapeutics in patients with cardiovascular diseases.
Here, we show that C3aR −/− mice have reduced stroke and myocardial infarction after ischemia/reperfusion injury, whereas there was no longer a difference between WT and knockout mice in the absence of platelets, indicating a functional role of the C3aR on platelets in this setting of thrombotic disease. Neutrophils and a cross-talk of platelets with neutrophils are known to contribute to ischemia/reperfusion injury. 58 Although the difference between WT and C3aR −/− mice persisted after neutrophil depletion in our experiments, at this point, we cannot entirely rule out any functional relevance of the C3aR on neutrophils for myocardial infarction, which will have to be addressed in future studies. Our findings support the hypothesis that the complement cascade, especially the C3-C3a-C3aR axis, is a "sweet spot" for therapeutic intervention and confirm the potential relevance of drugs modulating the complement cascade on the level of C3.
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CONCLUSIONS
Our observations demonstrate, to the best of our knowledge for the first time, a functional role of the anaphylatoxin receptor C3aR expressed on platelets for thrombosis and hemostasis in vivo. Our findings suggest that targeting C3aR on platelets could be a potential point for therapeutic interventions and for the development of further complement inhibitors. This report thus identified a novel intersection point between 2 central systems of host defense and tissue repair: the complement cascade and platelet activation.
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